Development of a polymer system for the delivery of daunorubicin to tumor cells to overcome drug resistance
- Авторы: Nikolskaya E.D.1, Faustova M.R.1, Mollaev M.D.1, Zhunina O.A.2, Sokol M.B.2, Yabbarov N.G.2, Gukasova N.V.3, Lobanov A.V.4, Shvets V.I.1, Severin E.S.2
-
Учреждения:
- Moscow Technological University, M. V. Lomonosov Institute for Fine Chemical Technologies
- Russian Research Center for Molecular Diagnostics and Therapy
- National Research Center Kurchatov Institute
- N. N. Semenov Institute of Chemical Physics, Russian Academy of Sciences
- Выпуск: Том 67, № 4 (2018)
- Страницы: 747-756
- Раздел: Full Article
- URL: https://bakhtiniada.ru/1066-5285/article/view/242462
- DOI: https://doi.org/10.1007/s11172-018-2132-5
- ID: 242462
Цитировать
Аннотация
Method for the synthesis of polymeric nanoparticles (NP) with encapsulated daunorubicin (DNR) was developed on the basis of double emulsion solvent evaporation technique using biodegradable poly(lactide-co-glycolide) (PLGA), which is aimed at customization of pharmacokinetic properties of the preparation, enhanced accumulation of DNR in tumor cells and prolongation of its action. The obtained polymer nanoparticles (DNR-PLGA) had average size ranging around 138±36 nm, with zeta-potential of –25.3 mV and the polydispersity index (PDI) of 0.072. The release kinetics of DNR from polymer nanoparticles at pH 7.4 and 5.0 has been studied. In vitro studies showed similar specific activity of DNR- PLGA in K562 and MCF-7 cancer cell lines together with an increase in activity in K562 Adr and MCF-7 Adr cell lines, which are anthracycline resistant, by 1.6 and 3.4 times. The study demonstrated the efficacy of the developed PLGA-based DNR delivery system in the improvement of antitumor effect of DNR, overcoming multidrug resistance in cancer cells, and also in the decrease in nonspecific toxicity of the preparation.
Об авторах
E. Nikolskaya
Moscow Technological University, M. V. Lomonosov Institute for Fine Chemical Technologies
Email: e.sverin@mail.ru
Россия, 86 prosp. Vernadskogo, Moscow, Russian Federation, 119571
M. Faustova
Moscow Technological University, M. V. Lomonosov Institute for Fine Chemical Technologies
Email: e.sverin@mail.ru
Россия, 86 prosp. Vernadskogo, Moscow, Russian Federation, 119571
M. Mollaev
Moscow Technological University, M. V. Lomonosov Institute for Fine Chemical Technologies
Email: e.sverin@mail.ru
Россия, 86 prosp. Vernadskogo, Moscow, Russian Federation, 119571
O. Zhunina
Russian Research Center for Molecular Diagnostics and Therapy
Email: e.sverin@mail.ru
Россия, 8 Simpheropol’sky bulvar, Moscow, Russian Federation, 117149
M. Sokol
Russian Research Center for Molecular Diagnostics and Therapy
Email: e.sverin@mail.ru
Россия, 8 Simpheropol’sky bulvar, Moscow, Russian Federation, 117149
N. Yabbarov
Russian Research Center for Molecular Diagnostics and Therapy
Email: e.sverin@mail.ru
Россия, 8 Simpheropol’sky bulvar, Moscow, Russian Federation, 117149
N. Gukasova
National Research Center Kurchatov Institute
Email: e.sverin@mail.ru
Россия, 1 pl. Akad. Kurchatova, Moscow, Russian Federation, 123182
A. Lobanov
N. N. Semenov Institute of Chemical Physics, Russian Academy of Sciences
Email: e.sverin@mail.ru
Россия, 4 ul. Kosygina, Moscow, Russian Federation, 119991
V. Shvets
Moscow Technological University, M. V. Lomonosov Institute for Fine Chemical Technologies
Автор, ответственный за переписку.
Email: shvetsviiv@gmail.com
Россия, 86 prosp. Vernadskogo, Moscow, Russian Federation, 119571
E. Severin
Russian Research Center for Molecular Diagnostics and Therapy
Автор, ответственный за переписку.
Email: e.sverin@mail.ru
Россия, 8 Simpheropol’sky bulvar, Moscow, Russian Federation, 117149
Дополнительные файлы
